Hematology/Oncology, BreakingMed | Physician's Weekly
Advertisement

Hematology/Oncology, BreakingMed

ASCO: Breast Cancer Brain Mets Treated with Tucatinib

Addition of agent to chemotherapy improves survival The risk of death or progression of brain metastases was reduced if patients with breast cancer added tucatinib (Tukysa) to a regimen of trastuzumab and capecitabine,...

ASCO: Larotrectinib Produces Durable Responses

TRK fusion targets multiple cancers Patients diagnosed with a variety of advanced cancers — from thyroid to breast cancer — appear to have durable responses when treated with larotrectinib (Vitrakvi), an agent that...

ASCO: Survival Benefit Emerges in ARAMIS

Darolutamide better in non-metastatic castration-resistant prostate cancer Men diagnosed with non-metastatic castration-resistant prostate cancer live longer if they are treated with darolutamide (Nubeqa) than placebo, the final...

ASCO: Consultant Palliation Improves AML Quality of Life

Early referral linked to better psychological outcomes Referring a patient diagnosed with acute myeloid leukemia (AML) to the palliation service at the time grueling therapy begins appears to offer psychological benefits down...

Loading

Advertisement

For latest news and updates
Email-id is invalid